Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers

JAMA Oncology

Volumn 1, Issue 3, 2015, Pages 306-313

  Metcalfe, Kelly ^a,b   Lynch, Henry T ^c   Foulkes, William D ^d   Tung, Nadine ^e   Kim Sing, Charmaine ^f   Olopade, Olufunmilayo I ^g   Eisen, Andrea ^h   Rosen, Barry ⁱ   Snyder, Carrie ^c   Gershman, Shelley ^a,b   Sun, Ping ^a   Narod, Steven A ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g UNIVERSITY OF CHICAGO   (United States)

^h DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVERSE EFFECTS; AGED; BREAST NEOPLASMS; CANADA; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; FEMALE; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; HUMAN; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; OVARIAN NEOPLASMS; OVARIECTOMY; PATHOLOGY; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADULT; AGED; BIOMARKERS, TUMOR; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CANADA; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84965093396     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.0658     Document Type: Article

References (17)

1. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-1130.
2. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328-2335.
3. Metcalfe KA, Lynch HT, Ghadirian P, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96(1):222-226.
4. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23(30):7491-7496.
5. Finch A, Beiner M, Lubinski J, et al; Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296(2):185-192.
6. ACOG Committee on Practice Bulletins. Hereditary breast and ovarian cancer syndrome. Gynecol Oncol. 2009;113(1):6-11.
7. Finch AP, Lubinski J, Møller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547-1553.
8. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975.
9. Huzarski T, Byrski T, Gronwald J, et al. Ten year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol. 2013;31(26):3191-3196.
10. Valentini A, Lubinski J, Byrski T, et al; Hereditary Breast Cancer Clinical Study Group. The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2013;142(1):177-185.
11. Møller P, Stormorken A, Jonsrud C, et al. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program. Breast Cancer Res Treat. 2013;139(1):155-161.
12. Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226.
13. Narod SA. Should all women with breast cancer be tested for BRCA mutations at the time of diagnosis?J Clin Oncol. 2012;30(1):2-3.
14. Finch A, Valentini A, Greenblatt E, et al; Hereditary Breast Cancer Study Group. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation.Fertil Steril. 2013;99(6):1724-1728.
15. Kotsopoulos J, Lubinski J, Lynch HT, et al. Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev.2012;21(7):1089-1096.
16. Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28(3):375-379.
17. Narod SA, Metcalfe K, Lynch HT, et al. Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat. 2013;138(1):273-279.